Skip to main content
DOUBLE MEDICAL TECHNOLOGY INC. logo

DOUBLE MEDICAL TECHNOLOGY INC. — Investor Relations & Filings

Ticker · 002901 ISIN · CNE1000032W7 LEI · 836800DECKX5CGFNMD42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 963 across all filing types
Latest filing 2026-05-21 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002901

About DOUBLE MEDICAL TECHNOLOGY INC.

https://www.double-medical.com

Double Medical Technology Inc. specializes in the development, manufacturing, and distribution of medical devices, with a primary focus on orthopedic solutions. The company's extensive product portfolio includes trauma fixation systems, spinal implants, joint prosthesis, and neurosurgical devices. Additionally, it provides specialized surgical instruments and advanced wound care products. Double Medical emphasizes research and innovation to deliver clinically effective solutions for complex musculoskeletal conditions. Its manufacturing processes adhere to international quality standards, ensuring the reliability of its implants and instruments used in hospitals and surgical centers worldwide. The company serves a global market, providing comprehensive support for orthopedic surgeons through its diverse range of reconstructive and regenerative medical technologies.

Recent filings

Filing Released Lang Actions
关于首次回购股份的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement by the company and its board regarding the first share repurchase under an approved share buyback plan, detailing the number of shares repurchased, prices, amounts, and regulatory compliance. This fits the “Transaction in Own Shares” category (POS).
2026-05-21 Chinese
关于回购公司股份方案的公告暨回购报告书
Transaction in Own Shares Classification · 97% confidence The document is a detailed announcement and plan for a share repurchase by the company, including the amount, method, purpose (equity incentive), timeline, and related disclosures. This falls squarely under “Transaction in Own Shares” (share buyback) rather than an earnings report, proxy, or other category.
2026-05-19 Chinese
第四届董事会第五次会议决议公告
Transaction in Own Shares Classification · 85% confidence The document is a board of directors meeting resolution announcement detailing the company’s plan to repurchase its own shares (size, price, period). This is a direct announcement of a share buyback transaction by the company. Under the classification schema, such disclosures are categorized as Transaction in Own Shares (POS).
2026-05-19 Chinese
关于召开2026年第二次临时股东会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2026 second extraordinary general meeting of shareholders (临时股东会) for the company 大博医疗科技股份有限公司. It includes details about the meeting time, location, agenda proposals, voting procedures, and registration requirements. It does not contain financial statements, audit opinions, or detailed financial results. It is a formal announcement to shareholders about the meeting and how to participate, including proxy forms and voting instructions. The document length is 4229 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual or Extraordinary General Meeting.
2026-03-23 Chinese
关于2026年度公司申请银行综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application for a comprehensive bank credit facility for the year 2026. It details the credit limits requested from various banks and the authorization given to the chairman to handle related matters. There are no financial statements, audit information, or detailed financial results presented. The document is relatively short (783 characters) and serves as an update on financing activities rather than a full financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-03-23 Chinese
关于开展2026年度外汇衍生品交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company regarding the approval and plan to conduct foreign exchange derivative transactions for the year 2026. It details the purpose, scope, risk analysis, risk control measures, and accounting treatment related to these transactions. The document is a formal announcement of a corporate decision made by the board and pending shareholder approval. It does not contain financial statements, quarterly or annual financial results, or detailed financial data. It is not a report but an announcement of a business activity and related governance. Therefore, it fits best under Capital/Financing Update (CAP), as it relates to the company's financing activities and risk management involving foreign exchange derivatives.
2026-03-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.